RxDoctor Payments Data

Danielle Andrusko

Adult Health · Staten Island, NYNPI 1285925313

Payments from drug & device makers

$4,886in general payments, 2019–2025

Across 208 payments — averaging $23.49 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Johnson & Johnson$977
  • AbbVie$877
  • QOL Medical, LLC$369
  • Takeda Pharmaceuticals U.S.A., Inc.$362
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$349
  • Madrigal Pharmaceuticals$338
  • plus $2K from 19 others

What the payments were for

  • Food & beverage$4,876100%
  • Education$100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$4,886 in reported general payments places this provider in the 90th percentile of 3,828 adult health providers in New York.

See all adult health providers in New York

Medicare billing

Part B allowed, 2024
$77,350
Medicare patients
563
Services billed
661

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
ZenpepLipase/Protease/Amylase13$35,803
XifaxanRifaximin12$34,012
LinzessLinaclotide12$8,141
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates113$6,979
Mesalamine18$4,902
Pantoprazole Sodium129$2,345
Omeprazole189$2,286
Famotidine101$2,143
CholestyramineCholestyramine (With Sugar)19$1,424
Sucralfate18$1,386
Dicyclomine Hcl59$966
Esomeprazole Magnesium27$916
Ursodiol12$741
Lactulose13$267
Lansoprazole11$195

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Aimmune Therapeutics, Inc.Zenpep$53$35,80313 claims
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$349$34,01212 claims
AbbVieLinzess$877$8,14112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 3,828 adult health providers in New York.

Other adult health in Staten Island

See the full list for New York

Where these figures come from

Is this you, or does something look wrong? →